FI78302C - Foerfarande foer framstaellning av nya pyranoderivat. - Google Patents
Foerfarande foer framstaellning av nya pyranoderivat. Download PDFInfo
- Publication number
- FI78302C FI78302C FI851577A FI851577A FI78302C FI 78302 C FI78302 C FI 78302C FI 851577 A FI851577 A FI 851577A FI 851577 A FI851577 A FI 851577A FI 78302 C FI78302 C FI 78302C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- soluble
- tottoli
- water
- insoluble
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 14
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 10
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 7
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 4
- 229910052727 yttrium Inorganic materials 0.000 claims abstract description 3
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 6
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 4
- 238000004172 nitrogen cycle Methods 0.000 claims description 4
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 3
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 150000003290 ribose derivatives Chemical class 0.000 claims description 2
- 239000005051 trimethylchlorosilane Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 150000002243 furanoses Chemical class 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000003085 diluting agent Substances 0.000 abstract 1
- 150000003215 pyranoses Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 84
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 83
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 74
- 239000000843 powder Substances 0.000 description 69
- 239000000047 product Substances 0.000 description 57
- 238000004458 analytical method Methods 0.000 description 40
- 230000035484 reaction time Effects 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 5
- 229960004150 aciclovir Drugs 0.000 description 5
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 5
- 238000005056 compaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
- 206010046555 Urinary retention Diseases 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- HMFHBZSHGGEWLO-ZRMNMSDTSA-N D-arabinofuranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H]1O HMFHBZSHGGEWLO-ZRMNMSDTSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HMFHBZSHGGEWLO-SQOUGZDYSA-N beta-D-arabinofuranose Chemical compound OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H]1O HMFHBZSHGGEWLO-SQOUGZDYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-TXICZTDVSA-N beta-D-ribopyranose Chemical compound O[C@@H]1CO[C@@H](O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-TXICZTDVSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000005723 virus inoculator Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- SRBFZHDQGSBBOR-ZRMNMSDTSA-N D-arabinopyranose Chemical compound O[C@@H]1COC(O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-ZRMNMSDTSA-N 0.000 description 2
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 2
- 206010048461 Genital infection Diseases 0.000 description 2
- HMFHBZSHGGEWLO-MBMOQRBOSA-N alpha-D-arabinofuranose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H]1O HMFHBZSHGGEWLO-MBMOQRBOSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- HMFHBZSHGGEWLO-KKQCNMDGSA-N beta-D-xylofuranose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-KKQCNMDGSA-N 0.000 description 2
- SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical compound O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000313 electron-beam-induced deposition Methods 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FEOOHOXQNOVDKV-RKEPMNIXSA-N 1-[(3R,4S,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]ethanone Chemical compound C(C)(=O)C1(O)[C@H](O)[C@H](O)[C@H](O1)CO FEOOHOXQNOVDKV-RKEPMNIXSA-N 0.000 description 1
- -1 2,3,4-tri-O-acetylxylopyranosyl Chemical group 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- WFJXYIUAMJAURQ-UHFFFAOYSA-N 2-propan-2-ylsulfinylpropane Chemical compound CC(C)S(=O)C(C)C WFJXYIUAMJAURQ-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- TUUGFLAHJMHZFV-UHFFFAOYSA-N 3-hydroxy-2-phenyl-1h-pyrazol-5-one Chemical compound OC1=CC(=O)NN1C1=CC=CC=C1 TUUGFLAHJMHZFV-UHFFFAOYSA-N 0.000 description 1
- NZEXWHARPPMMIQ-UHFFFAOYSA-N 4-methyl-2-phenyl-1h-pyrano[2,3-c]pyrazole-3,6-dione Chemical compound O=C1C=2C(C)=CC(=O)OC=2NN1C1=CC=CC=C1 NZEXWHARPPMMIQ-UHFFFAOYSA-N 0.000 description 1
- BSPLJSZIXJDUPP-UHFFFAOYSA-N 5-chloro-4-methylpyrano[2,3-c]pyrazole-3,6-dione Chemical compound CC1=C(C(OC=2N=NC(C=21)=O)=O)Cl BSPLJSZIXJDUPP-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Chemical group OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-SQOUGZDYSA-N beta-D-arabinopyranose Chemical compound O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04H—BUILDINGS OR LIKE STRUCTURES FOR PARTICULAR PURPOSES; SWIMMING OR SPLASH BATHS OR POOLS; MASTS; FENCING; TENTS OR CANOPIES, IN GENERAL
- E04H1/00—Buildings or groups of buildings for dwelling or office purposes; General layout, e.g. modular co-ordination or staggered storeys
- E04H1/12—Small buildings or other erections for limited occupation, erected in the open air or arranged in buildings, e.g. kiosks, waiting shelters for bus stops or for filling stations, roofs for railway platforms, watchmen's huts or dressing cubicles
- E04H1/1272—Exhibition stands
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
- F16B2/00—Friction-grip releasable fastenings
- F16B2/20—Clips, i.e. with gripping action effected solely by the inherent resistance to deformation of the material of the fastening
Landscapes
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Architecture (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mechanical Engineering (AREA)
- Veterinary Medicine (AREA)
- Civil Engineering (AREA)
- Structural Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848410484A GB8410484D0 (en) | 1984-04-24 | 1984-04-24 | Antiviral and antibacterial compounds |
| GB8410484 | 1984-04-24 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI851577A0 FI851577A0 (fi) | 1985-04-22 |
| FI851577L FI851577L (fi) | 1985-10-25 |
| FI78302B FI78302B (fi) | 1989-03-31 |
| FI78302C true FI78302C (fi) | 1989-07-10 |
Family
ID=10560013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI851577A FI78302C (fi) | 1984-04-24 | 1985-04-22 | Foerfarande foer framstaellning av nya pyranoderivat. |
| FI851576A FI78301C (fi) | 1984-04-24 | 1985-04-22 | Foerfarande foer framstaellning av nya bornanderivat. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI851576A FI78301C (fi) | 1984-04-24 | 1985-04-22 | Foerfarande foer framstaellning av nya bornanderivat. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US4720487A (enExample) |
| JP (2) | JPS60233095A (enExample) |
| AR (2) | AR241916A1 (enExample) |
| AT (2) | AT388557B (enExample) |
| BE (2) | BE902231A (enExample) |
| CA (2) | CA1241649A (enExample) |
| CH (2) | CH665837A5 (enExample) |
| DE (2) | DE3514641A1 (enExample) |
| DK (2) | DK160833C (enExample) |
| DZ (1) | DZ772A1 (enExample) |
| ES (2) | ES8606380A1 (enExample) |
| FI (2) | FI78302C (enExample) |
| FR (3) | FR2563107B1 (enExample) |
| GB (3) | GB8410484D0 (enExample) |
| HK (2) | HK18788A (enExample) |
| IE (2) | IE58322B1 (enExample) |
| IT (2) | IT1201415B (enExample) |
| LU (2) | LU85865A1 (enExample) |
| MA (2) | MA20414A1 (enExample) |
| MY (1) | MY102313A (enExample) |
| NL (2) | NL193067C (enExample) |
| NO (2) | NO161121C (enExample) |
| OA (2) | OA08000A (enExample) |
| PT (2) | PT80325B (enExample) |
| SE (2) | SE462972B (enExample) |
| ZA (2) | ZA852367B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3868361A (en) * | 1973-03-12 | 1975-02-25 | Richard L Tolman | s-Triazolo{8 2,3-A{9 {0 pryimidine nucleosides |
| DE3019322A1 (de) * | 1980-05-21 | 1981-12-03 | Merck Patent Gmbh, 6100 Darmstadt | Psychopharmakon sowie verwendung von adenosinderivaten |
-
1984
- 1984-04-24 GB GB848410484A patent/GB8410484D0/en active Pending
-
1985
- 1985-03-28 ZA ZA852367A patent/ZA852367B/xx unknown
- 1985-03-28 ZA ZA852366A patent/ZA852366B/xx unknown
- 1985-04-01 US US06/718,065 patent/US4720487A/en not_active Expired - Fee Related
- 1985-04-01 US US06/718,064 patent/US4704454A/en not_active Expired - Fee Related
- 1985-04-10 AR AR85300028A patent/AR241916A1/es active
- 1985-04-10 AR AR85300029A patent/AR241917A1/es active
- 1985-04-17 SE SE8501884A patent/SE462972B/sv not_active IP Right Cessation
- 1985-04-17 SE SE8501885A patent/SE462973B/sv not_active IP Right Cessation
- 1985-04-18 BE BE0/214871A patent/BE902231A/fr not_active IP Right Cessation
- 1985-04-18 CH CH1665/85A patent/CH665837A5/fr not_active IP Right Cessation
- 1985-04-18 CH CH1666/85A patent/CH664572A5/fr not_active IP Right Cessation
- 1985-04-18 BE BE0/214872A patent/BE902232A/fr not_active IP Right Cessation
- 1985-04-19 MA MA20638A patent/MA20414A1/fr unknown
- 1985-04-19 MA MA20639A patent/MA20415A1/fr unknown
- 1985-04-22 PT PT80325A patent/PT80325B/pt not_active IP Right Cessation
- 1985-04-22 FI FI851577A patent/FI78302C/fi not_active IP Right Cessation
- 1985-04-22 IT IT20440/85A patent/IT1201415B/it active
- 1985-04-22 LU LU85865A patent/LU85865A1/fr unknown
- 1985-04-22 PT PT80324A patent/PT80324B/pt not_active IP Right Cessation
- 1985-04-22 FI FI851576A patent/FI78301C/fi not_active IP Right Cessation
- 1985-04-22 IT IT8520439A patent/IT1215265B/it active
- 1985-04-22 LU LU85864A patent/LU85864A1/fr unknown
- 1985-04-23 IE IE102985A patent/IE58322B1/en not_active IP Right Cessation
- 1985-04-23 IE IE103085A patent/IE58323B1/en not_active IP Right Cessation
- 1985-04-23 ES ES542486A patent/ES8606380A1/es not_active Expired
- 1985-04-23 CA CA000479844A patent/CA1241649A/en not_active Expired
- 1985-04-23 DZ DZ850084A patent/DZ772A1/fr active
- 1985-04-23 GB GB08510328A patent/GB2157690B/en not_active Expired
- 1985-04-23 DE DE19853514641 patent/DE3514641A1/de active Granted
- 1985-04-23 ES ES542485A patent/ES8606379A1/es not_active Expired
- 1985-04-23 NL NL8501171A patent/NL193067C/nl not_active IP Right Cessation
- 1985-04-23 GB GB08510329A patent/GB2158436B/en not_active Expired
- 1985-04-23 NL NL8501170A patent/NL193109B/xx not_active Application Discontinuation
- 1985-04-23 DK DK181385A patent/DK160833C/da not_active IP Right Cessation
- 1985-04-23 NO NO851619A patent/NO161121C/no unknown
- 1985-04-23 NO NO851620A patent/NO161122C/no unknown
- 1985-04-23 DK DK181285A patent/DK160832C/da not_active IP Right Cessation
- 1985-04-23 CA CA000479845A patent/CA1265129A/en not_active Expired - Lifetime
- 1985-04-23 DE DE19853514637 patent/DE3514637A1/de active Granted
- 1985-04-24 JP JP60086616A patent/JPS60233095A/ja active Granted
- 1985-04-24 AT AT0122585A patent/AT388557B/de not_active IP Right Cessation
- 1985-04-24 OA OA58577A patent/OA08000A/xx unknown
- 1985-04-24 FR FR8506206A patent/FR2563107B1/fr not_active Expired
- 1985-04-24 JP JP60086617A patent/JPS60233096A/ja active Granted
- 1985-04-24 FR FR8506204A patent/FR2563106B1/fr not_active Expired
- 1985-04-24 OA OA58576A patent/OA07999A/xx unknown
- 1985-04-24 FR FR8506207A patent/FR2563224B1/fr not_active Expired
- 1985-04-24 AT AT0122685A patent/AT388558B/de not_active IP Right Cessation
-
1988
- 1988-01-26 MY MYPI88000060A patent/MY102313A/en unknown
- 1988-03-10 HK HK187/88A patent/HK18788A/xx not_active IP Right Cessation
-
1989
- 1989-02-02 HK HK102/89A patent/HK10289A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Srivastava et al. | Synthesis and antiviral activity of certain thiazole C-nucleosides | |
| JPH08501071A (ja) | １，５−アンヒドロヘキシトールヌクレオシド類似体および該類似体の医薬としての使用 | |
| DK169657B1 (da) | Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider | |
| NO154344B (no) | Analogifremgangsmaate for fremstilling av antivirale amin- og amidin-derivater. | |
| US4383114A (en) | Adenosine deaminase resistant antiviral purine arabinonucleosides | |
| EP0296573A2 (en) | Novel nucleosides, their preparation and pharmaceutical compositions | |
| JP2941942B2 (ja) | ３’―アジド―２’，３’―ジデオキシ―５―メチルシチジン抗ウィルス性組成物 | |
| HU201090B (en) | Process for producing dideoxocytidine derivatives and pharmaceutical compositions comprising same as active ingredient | |
| US3991190A (en) | Treatment of viral infections | |
| CA1318850C (en) | Pharmaceutical products | |
| FI78302B (fi) | Foerfarande foer framstaellning av nya pyranoderivat. | |
| JPS595117A (ja) | ウイルス性疾患治療剤 | |
| Kumar et al. | Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine | |
| FI67556C (fi) | Foerfarande foer framstaellning av nya saosom antivirala medelanvaendbara substituerade acetofenonderivat | |
| US5077279A (en) | 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition | |
| FI86637B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara tiazolo/3,2a/ pyrimidinderivat. | |
| KR870001935B1 (ko) | 항포진성을 갖는 뉴클레오시 유도체 및 그의 산부가염의 제조방법 | |
| US4939156A (en) | New tetramethyl-cis-diaza-bicyclo{4.2.0}octane-3,5-dione derivatives having differentiation-inducing activity and antiviral activity | |
| ITMI950811A1 (it) | Pirrolobenzotiadiazepine e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids | |
| CS208156B2 (cs) | Způsob výroby nových aminových derivátů propandiolů | |
| SA92120445B1 (ar) | إستخدام deoxy-3"thiacytidine 5-fluoro- 2" من اجل علاج فيروس الكبد الوبائي B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D APPLICATION |